nature neurOSCIenCe a r t I C l e S Opioid analgesics are ubiquitous in modern medicine, and the non-medical use and abuse of prescription opioids are becoming increasingly prevalent [1] [2] [3] [4] . Thus, a mechanistic understanding of the long-term effects of opioid exposure on brain function is critical. Mu (MOPr), delta (DOPr) and kappa (KOPr) G protein-coupled opioid receptors are abundantly expressed throughout the CNS 5 , as are their endogenous peptide ligands (the enkephalins, endorphins and dynorphins) 6, 7 , and the peptidases responsible for terminating the actions of these ligands [8] [9] [10] . Acting on central opioid receptors, opioid analgesics can markedly modify neurotransmission and alter endogenous forms of synaptic plasticity, including long-term potentiation and LTD [11] [12] [13] . Moreover, endogenous opioid peptides have recently been shown to induce long-term plasticity in the hypothalamus and hippocampus [14] [15] [16] [17] . Given the widespread central expression of the endogenous opioid system, opioid-mediated long-term plasticity may exist in many brain regions.
a r t I C l e S
Opioid analgesics are ubiquitous in modern medicine, and the non-medical use and abuse of prescription opioids are becoming increasingly prevalent [1] [2] [3] [4] . Thus, a mechanistic understanding of the long-term effects of opioid exposure on brain function is critical. Mu (MOPr), delta (DOPr) and kappa (KOPr) G protein-coupled opioid receptors are abundantly expressed throughout the CNS 5 , as are their endogenous peptide ligands (the enkephalins, endorphins and dynorphins) 6, 7 , and the peptidases responsible for terminating the actions of these ligands [8] [9] [10] . Acting on central opioid receptors, opioid analgesics can markedly modify neurotransmission and alter endogenous forms of synaptic plasticity, including long-term potentiation and LTD [11] [12] [13] . Moreover, endogenous opioid peptides have recently been shown to induce long-term plasticity in the hypothalamus and hippocampus [14] [15] [16] [17] . Given the widespread central expression of the endogenous opioid system, opioid-mediated long-term plasticity may exist in many brain regions.
The endogenous opioid system is prominent in the dorsal striatum, the major input nucleus of the basal ganglia. Glutamatergic inputs to the dorsal striatum arise from sensorimotor and association cortices and thalamic nuclei [18] [19] [20] and synapse onto GABAergic medium spiny neurons (MSNs), the principal projection neurons of the striatum 21 . Exogenous opioid agonists 22, 23 and endogenous opioid peptides, released following antidromic activation of MSNs by stimulation of the globus pallidus 24 , suppress glutamatergic transmission onto MSNs, likely via presynaptic opioid receptors. However, no work to date has found evidence of long-lasting, opioid-mediated plasticity in the striatum. We explored the ability of exogenous and endogenous opioids to induce long-term synaptic plasticity of excitatory transmission in the dorsal striatum. We further probed the effects of acute in vivo exposure to the opioid analgesic oxycodone on striatal opioid-mediated plasticity and, by optogenetically targeting cortical and thalamic inputs to the dorsal striatum, asked whether this plasticity is input specific.
RESULTS

Opioid receptor activation produces LTD in dorsal striatum
Bath application of the MOPr agonist DAMGO induced a long-lasting reduction of electrically evoked excitatory postsynaptic current (eEPSC) amplitude in MSNs in the dorsolateral striatum (DLS, 64.6 ± 5.9%, data are presented as mean ± s.e.m. % of baseline; Fig. 1a) . We termed this effect mu opioid peptide long-term depression (mOP-LTD), as the selective MOPr antagonist CTAP prevented synaptic depression when applied throughout the recording (93.9 ± 6.0%; Fig. 1b ), but did not reverse the depression when applied after cessation of DAMGO application (58.7 ± 5.1%). DAMGO also reduced net striatal output, as measured by population spike amplitude in extracellular field recordings in the DLS (Supplementary Fig. 1a) . The DOPr agonist DPDPE similarly induced OP-LTD (dOP-LTD) of eEPSC amplitude in DLS MSNs (73.6 ± 2.8%; Fig. 1c) . The selective DOPr antagonist naltrindole (NTI) blocked DPDPE-induced depression (90.2 ± 5.8%; Fig. 1d ), but did not reverse established depression (63.6 ± 2.1). DPDPE also reduced population spike amplitude in extracellular field recordings (Supplementary Fig. 1b) . Despite prior evidence that KOPr-mediated inhibition of excitatory transmission does not occur in dorsal striatum 22 , the KOPr agonist U69,593 produced LTD of eEPSCs in the DLS (77.6 ± 2.8%; Fig. 1e ). Nor-BNI, a KOPr antagonist, blocked (91.2 ± 3.4%; Fig. 1f ), but did not reverse, this effect (74.7 ± 6.0%). U69,593 also induced LTD in field potential recordings (Supplementary Fig. 1c ). OP-LTD induced by each agonist in the DLS was robust at two holding potentials −60 and −80 mV) observed under physiological conditions in striatal MSNs 25 (Supplementary Fig. 2 ). DAMGO and DPDPE induced a r t I C l e S LTD of excitatory transmission to the same extent in MSNs in the dorsomedial striatum (DMS) as in DLS MSNs ( Supplementary  Fig. 2a,b) . In contrast, U69,593 had little to no effect in the DMS ( Supplementary  Fig. 2c ), indicating that kOP-LTD is uniquely subregion specific.
Multiple forms of excitatory LTD in the dorsal striatum are expressed as presynaptic inhibition of glutamate release 26, 27 . To assess the synaptic site of OP-LTD expression, we examined the effects of opioid receptor agonists on the ratio of synaptic responses to paired pulses (50-ms interval), a measure that changes reliably with release probability. Both DAMGO and DPDPE induced a prolonged increase in the mean paired-pulse ratio (PPR; DAMGO, 0.99 ± 0.09 to 1.18 ± 0.11; DPDPE, 1.09 ± 0.06 to 1.19 ± 0.06; Fig. 1g,h ), indicative of a persistent reduction in glutamate release probability. U69,593 induced a slower onset increase in PPR (1.08 ± 0.07 to 1.19 ± 0.08; Fig. 1i ). To further assess the site of OP-LTD expression, we tested the effects of opioid agonists on the frequency and amplitude of spontaneous EPSCs (sEPSCs). DAMGO ( Supplementary Fig. 3a-d) and DPDPE ( Supplementary  Fig. 3e-h ) induced prolonged increases in sEPSC inter-event interval (IEI), but not amplitude, reflecting a decrease in presynaptic glutamate release. In contrast, sEPSC IEI was nonsignificantly attenuated (P = 0.0570) following washout of U69,593 ( Supplementary  Fig. 3i-k) , whereas sEPSC amplitude was significantly decreased (P = 0.0307) at the same time point (Supplementary Fig. 3i,l) . Taken together, these data suggest that mOP-and dOP-LTD of excitatory transmission likely result from a reduction of presynaptic glutamate release, whereas kOP-LTD appears to have a less clear, multifaceted locus of expression.
Endogenous opioids produce LTD Exogenous application of the endogenous opioid peptide metenkephalin (Met-Enk) suppresses excitatory transmission in the striatum through both MOPrs and DOPrs 22 . Bath application of Met-Enk produced LTD of eEPSC amplitude in DLS MSNs (67.3 ± 3.8%; Fig. 2a ) that was unaltered by pre-application of CTAP (76.8 ± 2.2%; Fig. 2b ), but was blocked by NTI (97.8 ± 9.1%; Fig. 2b,c) . NTI failed to reverse established Met-Enk-induced inhibition (74.6 ± 3.6%; Fig. 2c ). Leu-enkephalin (Leu-Enk) induced LTD (77.1 ± 3.9%; Fig. 2d ) that was modestly attenuated by pre-application of either CTAP (83.8 ± 5.2; Fig. 2e) npg a r t I C l e S receptor antagonist naloxone completely blocked (96.5 ± 4.6%; Fig. 2e,f) , but did not reverse (71.6 ± 7.4%; Fig. 2f ), Leu-Enk-induced depression. Dynorphin A also produced LTD (71.0 ± 4.3%; Fig. 2g ) that was not significantly altered (P > 0.05) by CTAP (88.0 ± 5.4%; Fig. 2h ), but completely blocked by nor-BNI (100.8 ± 5.1%; Fig. 2h,i) .
Once established, dynorphin-induced LTD was not reversed by nor-BNI (75.6 ± 4.2%; Fig. 2i ).
To determine whether endogenously released opioid peptides could induce LTD similar to exogenously applied ligands, we bath applied peptidase inhibitors to increase synaptic content of endogenous opioids. The neprilysin inhibitor bestatin reduced eEPSC amplitude (82.1 ± 2.2%; Fig. 3a) to a lesser extent than Met-Enk, Leu-Enk and dynorphin, as did dl-thiorphan and captopril, which are inhibitors of aminopeptidase N and angiotensin converting enzyme, respectively (dl-thiorphan, 90.2 ± 3.6%; captopril, 90.9 ± 4.0%; Fig. 3a) . A cocktail of the three peptidase inhibitors robustly reduced eEPSC amplitude (64 ± 7.0%; Fig. 3a,b) . Naloxone completely blocked (100.5 ± 4.1%; Fig. 3c,d ), but did not reverse (74.8 ± 5.0%; Fig. 3d) , inhibition by the cocktail, indicating that endogenously released opioid peptides can induce OP-LTD. Pre-application of selective antagonists for MOPrs, DOPrs and KOPrs each blocked the effects of the peptidase inhibitor cocktail (Fig. 3c) . These data implicate each opioid receptor in (Fig. 4a,b) that was blocked by pre-application of naloxone (Fig. 4b) . In the absence of electrical stimulation, the peptidase inhibitor cocktail had no effect on sEPSC IEI (Fig. 4b) , suggesting that the inhibitors alone failed to promote sufficient endogenous opioid signaling to induce OP-LTD. sEPSC amplitude did not change in any of these experiments (data not shown). Together, these data reveal that endogenous opioids act on opioid receptors to suppress presynaptic glutamate release in the DLS.
Given that electrical stimulation was necessary to produce endogenous OP-LTD (Fig. 4b) , we probed the mechanisms underlying activitydependent opioid peptide release. We found no role of dopamine signaling in OP-LTD, as combined application of the dopamine D1 and (Fig. 4c) . However, combined bath application of the mGluR1 and mGluR5 antagonists JNJ16259685 and MPEP (91.4 ± 4.1%), as well as application of MPEP alone (96.5 ± 6.2%), but not JNJ16259685 alone (75.6 ± 2.8%), completely blocked peptidase inhibitor-induced OP-LTD (Fig. 4c,d) . These results indicate a critical role for mGluR5 signaling in the activity-dependent release of opioid peptides underlying striatal OP-LTD and suggest that opioid peptides originating from the recorded MSN are not necessary to produce LTD.
mOP-and dOP-LTD operate independently
Given that mOP-and dOP-LTD are both expressed presynaptically and in MSNs throughout the dorsal striatum, we assessed whether mOP-and dOP-LTD are in fact dissociable forms of plasticity. To do so, we applied DAMGO and DPDPE sequentially. Following induction of stable mOP-LTD by DAMGO (71.6 ± 4.2%; Fig. 5a ), DPDPE further decreased eEPSC amplitude (60.5 ± 4.2% of original baseline). Conversely, following stable dOP-LTD induction by DPDPE (85.1 ± 1.2%; Fig. 5b ), DAMGO induced further depression of eEPSC amplitude (73.7 ± 4.4% of original baseline). These data suggest that MOPr and DOPr activation induce dissociable forms of LTD in the dorsal striatum. Endocannabinoid-mediated LTD, induced by pairing postsynaptic MSN depolarization with trains of high-frequency presynaptic stimulation, is a prominent form of plasticity in the DLS 26 . We tested whether eCB-LTD interacts with mOP-and dOP-LTD in a manner that may inform the mechanisms distinguishing these two forms of OP-LTD. Following eCB-LTD induction (82.3 ± 4.0%; Fig. 5c ), DAMGO induced a small reduction in eEPSC amplitude that returned to pre-DAMGO levels (77.4 ± 5.2% of original baseline). Similarly, after DAMGO-induced mOP-LTD (76.2 ± 5.1%; Fig. 5d ), eCB-LTD could not be induced (74 ± 3.9% of original baseline). These data reveal that mOP-and eCB-LTD are mutually occlusive. In contrast, following eCB-LTD induction (78.5 ± 2.9%; Fig. 5e ), DPDPE produced a further depression (61.9 ± 4.5% of original baseline), and after DPDPE-induced dOP-LTD (69.9 ± 5.3%; Fig. 5f ), eCB-LTD induction caused additional depression (49.4 ± 4.2% of original baseline). To determine whether the mutual occlusion of mOP-and eCB-LTD occurred at the presynaptic (receptor signaling) or postsynaptic (eCB production) level, we tested the effects of DAMGO on the depression induced by the presynaptic CB 1 receptor agonist WIN55,212-2. We found no difference between the effects of combined application of WIN55,212-2 and DAMGO and application of WIN55,212-2 alone (Supplementary Fig. 4) , suggesting presynaptic occlusion between MOPr-and CB 1 -mediated plasticity. Furthermore, the occlusion between mOP-and eCB-LTD was not simply a result of the recruitment of eCB signaling at CB 1 receptors by opioid receptor activation, as mOP-LTD (and dOP-LTD) occurred in the presence of the CB 1 receptor antagonist AM251 (Supplementary Fig. 5a,b) . Conversely, eCB-LTD persisted in the presence of naloxone (Supplementary Fig. 5c ). Taken together, these data indicate that mOP-LTD, but not dOP-LTD, is mutually occlusive with eCB-LTD at the presynaptic signaling level, further supporting the hypothesis that MOPrs and DOPrs exert similar, but dissociable, effects on excitatory transmission in the dorsal striatum.
One possible explanation for the dissociable nature of mOP-and dOP-LTD suggested by the pharmacological experiments is that the two receptors are expressed at synapses arising from different striatal inputs. Given that electrical stimulation at the border of the DLS and overlying white matter can nonselectively recruit both corticostriatal and thalamostriatal projections to the striatum, we virally expressed (Fig. 6a,b) . DAMGO application had no clear effect on optically evoked motor Figure 6 MOPrs and DOPrs differentially inhibit specific striatal inputs. (a) Expression of ChR2-Venus in thalamic nuclei following injection of AAV vector into thalamus and expression in dorsal striatal areas receiving thalamic input. Images are representative of four injected mice. Note that thalamic injections resulted in some Venus expression in overlying hippocampus. To evaluate possible contributions of hippocampal afferents to our observations, we explicitly injected ChR2-Venus AAV vector into the hippocampus. As expected, we observed no Venus-positive afferent fibers in dorsal striatum (Supplementary Fig. 6 ). 0%; Fig. 6c) , whereas it strongly inhibited thalamostriatal oEPSCs (Fig. 6c) . Thalamostriatal depression appeared to slowly reverse, so these cells were recorded for up to 60 min, over which time the gradual return to baseline continued. Notably, at an end-point equivalent to the corticostriatal experiments (45 min), thalamostriatal transmission was still depressed (64.6 ± 7.3%). In contrast with DAMGO, DPDPE produced OP-LTD of corticostriatal oEPSCs (71.9 ± 3.0%; Fig. 6d ), but produced little to no depression of thalamostriatal oEPSCs (90.2 ± 4.4%). Thus, MOPr and DOPr activation inhibits distinct striatal inputs, and the inhibition of thalamic inputs by MOPr activation markedly differs from that observed using electrical stimulation.
a r t I C l e S adeno-associated viral (AAV) vectors encoding a channelrhodopsin-2 (ChR2)-Venus fusion protein in the motor cortex or thalamic nuclei (targeting the central lateral and medial thalamic nuclei primarily) to test this hypothesis. Both cortical and thalamic injections of ChR2-venus resulted in robust expression in inputs to the DLS
mOP-and eCB-LTD are lost after in vivo oxycodone exposure The commonly prescribed and abused analgesic oxycodone is primarily a MOPr agonist 28, 29 . We tested whether in vivo administration of oxycodone could interfere with LTD in the dorsal striatum. Mice injected with saline (intraperitoneal) 1 h before being killed showed normal LTD in the DLS following bath application of DAMGO (75.4 ± 3.7%; Fig. 7a) , DPDPE (82.7 ± 2.6%; Fig. 7b ) and U69,593 (69.3 ± 2.5%; Fig. 7c ). However, in mice injected with oxycodone (1 mg per kg of body weight, intraperitoneal) 1 h before death, DAMGO-induced mOP-LTD was abolished (92.2 ± 5.3%; Fig. 7a) , whereas DPDPE-induced dOP-LTD remained intact (77.7 ± 4.8%; Fig. 7b) . U69,593-induced kOP-LTD was preserved, but was significantly diminished (81.9 ± 1.1%, P = 0.0195; Fig. 7c) . Peptidase inhibitor-induced LTD was also abolished in oxycodone-treated mice (saline, 81.5 ± 2.3%; oxycodone, 100.0 ± 1.4%; Fig. 7d) . Consistent with evidence that mOP-LTD and eCB-LTD are mutually occlusive, eCB-LTD was absent in mice injected with oxycodone (saline, 77.6 ± 5.6%; oxycodone, 95.6 ± 6.6%; Fig. 7e) . The disruption of eCB-LTD appeared to occur at, or downstream of, the level of CB 1 receptor activation, as LTD caused by bath application of the CB 1 receptor agonist WIN 55-212-2 was reduced in oxycodone-treated mice (saline, 72.8.5 ± 3.6%; oxycodone, 88.5 ± 2.7%; Fig. 7f) .
To probe the persistence of the effects of oxycodone on plasticity, we killed mice up to 4 d after an injection of oxycodone or saline and tested them for mOP-LTD induction. DAMGO failed to induce mOP-LTD in oxycodone-injected mice, relative to saline-injected mice, for up to 2 d post-injection, with full recovery at 4 d (Fig. 7g,h) . Taken together, these data are consistent with the notion that in vivo oxycodone exposure causes long-lasting disruptions in the subsequent induction of mOP-and eCB-LTD, but not dOP-or kOP-LTD.
DISCUSSION
We observed several distinct forms of OP-LTD mediated by MOPrs, DOPrs and KOPrs at excitatory synapses in the dorsal striatum. mOPand dOP-LTD were both expressed presynaptically and throughout the dorsal striatum, but were dissociable in that they summated, differentially occluded eCB-LTD and likely inhibited different striatal inputs. In contrast, kOP-LTD was less clearly presynaptic and occurred in the DLS, but not the DMS. Application of peptidase inhibitors revealed that endogenously released opioid peptides acting through MOPrs, DOPrs and KOPrs can induce robust OP-LTD. Furthermore, acute in vivo exposure to the opiate analgesic oxycodone selectively interfered with mOP-LTD and eCB-LTD for up to 2 d following drug exposure. Although these data are the first, to the best of our knowledge, to show OP-LTD in striatum, OP-LTD has been described at excitatory synapses in hypothalamus 14 and inhibitory synapses in hypothalamus 17 and hippocampus 16 , mediated by KOPrs, MOPrs and DOPrs, respectively. Opioids have also been shown to modulate the induction or expression of both LTD and long-term potentiation 12, 13, [30] [31] [32] . In addition, transient or reversible suppression of excitatory transmission by opioid receptor signaling has been reported in other brain areas, including the nucleus accumbens 33 .
Our findings help inform previous reports on opioid receptor function in the dorsal striatum. Evidence that antidromic activation of pallidal-projecting MSNs produces a MOPr-mediated inhibition of excitatory transmission in the dorsal striatum 24 suggests that enkephalins serve as the principal ligands for dorsal striatal MOPrs, as enkephalins 6 , but not beta-endorphin 7 , are abundantly expressed in the dorsal striatum. Consistent with this view, we found that Leu-Enk induced OP-LTD that was partially blocked by the MOPr antagonist CTAP. Considered alongside evidence that consumption of highly palatable food causes a surge of enkephalin in the DMS and that infusion of DAMGO into the DMS stimulates such consumption 34 , these findings point to an important role for enkephalin action at MOPrs in striatal function. Of course, enkephalins also act on DOPrs 22 , and behaviors such as ethanol consumption are known to be regulated by DOPrs in the dorsal striatum 35 . Furthermore, our findings identify a role for KOPrs in the dorsal striatum, whereas no clear KOPrmediated synaptic effects have previously been observed. In fact, the lack of kOP-LTD in the DMS reported here may explain why a previous study 22 failed to find KOPr-mediated plasticity in the dorsal striatum, if recordings were not made exclusively in the DLS.
Using peptidase inhibitors, we found a form of striatal LTD mediated by endogenously released opioid peptides. Consistent with the known redundancy in the proteolytic actions of peptidases against striatal Met-Enk 36 and opioid peptides more generally, endogenous OP-LTD was greatest when three peptidase inhibitors were used in combination. The fact that MOPr, DOPr and KOPr antagonists each partially reversed the LTD induced by the peptidase inhibitor cocktail suggests enhanced levels of both enkephalin and dynorphin. Our data also argue against a basal opioid peptide tone in the dorsal striatum, as the peptidase inhibitors failed to modify sEPSC frequency in the absence of electrical stimulation. This electrical stimulation appeared to provide the requisite glutamate to activate mGluR5 receptors and thereby promote opioid peptide release, similar to the mechanism of opioid release observed in the hypothalamus 17 . Unlike in the hypothalamus, however, the opioid peptides critical for the expression of striatal OP-LTD did not appear to originate from the recorded cell. Furthermore, numerous attempts to drive broader MSN activity independent of electrical afferent stimulation failed to produce peptidase inhibitor OP-LTD (data not shown), suggesting that GABAergic afferent and postsynaptic activation is insufficient for striatal OP-LTD, at least in our preparation. mGluR5-mediated opioid peptide release therefore appears to be a heterosynaptic phenomenon involving the diffusion of opioid peptides from their release sites to the synapses being probed.
The ability of MOPr and DOPr activation to induce dissociable forms of OP-LTD, as evidenced by their additive effects and differential occlusion with eCB-LTD and in vivo oxycodone exposure, is likely to arise from two possible scenarios. First, MOPrs and DOPrs may inhibit excitatory transmission through different downstream mechanisms. However, MOPrs and DOPrs are both G i/o -coupled GPCRs, and likely couple to similar effectors. A more likely alternative is that MOPrs and DOPrs inhibit transmission at different excitatory terminals in striatum. Electron microscopy of rat striatum revealed that MOPrs and DOPrs are rarely coexpressed on the same terminals, and instances of coexpression tend to occur on inhibitory, rather than excitatory, terminals 37 . Furthermore, in situ hybridization studies of rat brain found that MOPr mRNA is more densely npg a r t I C l e S expressed than DOPr mRNA in the thalamus; the opposite has been observed in many cortical areas known to project to the dorsal striatum 38, 39 . Consistent with these studies, we found that DOPr activation had little effect on thalamostriatal transmission, but induced LTD of inputs from motor cortex. In contrast, we found that MOPr activation produced no clear effect on these motor cortical inputs, but robustly depressed thalamostriatal transmission. Notably, this latter MOPr-mediated suppression does not model our electrical stimulation data well, nor does it appear to necessarily be LTD.
Two possible scenarios may account for the differences between electrically and optogenetically identified MOPr-mediated plasticity. First, MOPr-mediated depression may selectively occur at thalamostriatal inputs, and the mixed population of inputs activated by electrical stimulation, including a subset of the thalamostriatal inputs recruited by optogenetic activation, may exhibit a kinetically different form of MOPr-mediated depression. We could speculate that electrical stimulation preferentially activates cortical inputs, given our placement of the stimulating electrode at the border of the dorsal striatum and overlying white matter and the predominant innervation of MSNs by cortical versus thalamic inputs 40 . Alternatively, electrical stimulation may activate unidentified, presumably non-motor cortical, inputs that display mOP-LTD independent of the MOPr-mediated depression observed at thalamostriatal inputs. MOPr mRNA has been detected in other non-motor cortical regions 38, 39 ; thus, striatal inputs from these areas may be important sites of mOP-LTD expression.
Our data reveal a selective interaction between CB 1 and MOPr signaling, but not DOPr or KOPr signaling, in the dorsal striatum. These findings extend prior reports of a cannabinoid-MOPr interaction 41 . For example, rats chronically treated with CB 1 receptor agonists show impaired eCB-LTD and MOPr-mediated suppression of excitatory transmission in the nucleus accumbens 42 . The nature of the CB 1 -MOPr interaction that we observed is currently unclear, but possibly results from shared signaling pathways of CB 1 and MOPrs, as well as potential coexpression of the two receptors on the same excitatory terminals in the dorsal striatum. Notably, our data indicate that eCB-and mOP-LTD are not mutually dependent, as inhibiting one did not impair induction of the other. The basis of the dissociation between eCB-and dOP-LTD is similarly unknown, but is consistent with our evidence that mOP-and dOP-LTD are distinct. CB 1 receptors display a graded mediolateral expression profile in striatum, with the highest expression laterally 43 , whereas MOPrs and DOPrs are more uniform in their expression 44 . Given that these DMS and DLS subregions are preferentially recruited during different aspects of action learning and selection 18 , opioid-and eCB-mediated forms of plasticity in the striatum are likely to have unique roles in striataldependent behavior.
A single, non-contingent exposure to oxycodone induced longlasting disruptions in MOPr-and CB 1 receptor-mediated striatal plasticity, leaving dOP-and kOP-LTD intact. Given that oxycodone and its principal metabolite oxymorphone more selectively bind to MOPrs than other opioid receptors 28, 29 , it is plausible that oxycodone treatment induces a form of mOP-LTD in the dorsal striatum that occludes subsequent ex vivo attempts to induce MOPr-and CB 1 -LTD. This is an attractive possibility given that induction of mOP-LTD occludes CB 1 -LTD expression. An alternative explanation for oxycodone's effect is that oxycodone treatment may lead to long-lasting MOPr desensitization. Arguing against this explanation, however, presynaptic opioid receptors, such as those thought to contribute to striatal OP-LTD, are more resistant to desensitization than their postsynaptic counterparts 45, 46 . Opioid receptor downregulation or alterations in receptor-effector coupling may also be involved in the effects of oxycodone on mOP-LTD. The behavioral effects of oxycodoneinduced changes in striatal plasticity are also currently unknown. Recent reports have shown that chronic exposure to alcohol 47 or ∆9-tetrahydrocannabinol 48 that disrupt dorsal striatal eCB-LTD also modify dorsal striatal-dependent learning, including the transition from goal-directed to habitual responding 48 . These findings suggest that similar behavioral adaptations could occur following oxycodone exposure, and potentially contribute to the transition from controlled to compulsive opioid use.
In summary, we observed previously unknown opioid-mediated forms of long-term striatal plasticity that are differentially affected by opioid analgesic exposure. Exogenously applied and endogenously released opioid peptides induced robust OP-LTD of excitatory transmission in the dorsal striatum. MOPr, DOPr and KOPr activation induced distinct, yet parallel, forms of OP-LTD. The subregion specificity of kOP-LTD and input specificity of mOP-and dOP-LTD provide a foundation for new hypotheses regarding the role of opioid receptors in modulating specific components of striatal-based behaviors. As we learn more about the developmental and behavioral roles for opioid and eCB signaling in the striatum, the long-lasting disruptions to MOPr-and CB 1 -mediated striatal plasticity seen following acute exposure to a commonly used and abused prescription analgesic are likely to become increasingly relevant to clinical practice.
METhODS
Methods and any associated references are available in the online version of the paper. 
